{"id":"tislelizumab-oxaliplatin-capecitabine","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Hand-foot skin reaction"},{"rate":null,"effect":"Immune-related adverse events (fatigue, rash)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tislelizumab is a humanized PD-1 inhibitor that blocks the PD-1/PD-L1 checkpoint, allowing T cells to recognize and attack cancer cells. Oxaliplatin and capecitabine are chemotherapy agents that work synergistically—oxaliplatin is a platinum-based agent causing DNA damage, while capecitabine is a fluoropyrimidine prodrug that inhibits thymidylate synthase. The combination leverages immunotherapy with conventional chemotherapy for enhanced anti-tumor activity.","oneSentence":"This combination uses a PD-1 inhibitor to enhance immune response against cancer cells while chemotherapy agents directly kill rapidly dividing cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:39:04.247Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastric or gastroesophageal junction cancer (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT05152147","phase":"PHASE3","title":"A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jazz Pharmaceuticals","startDate":"2021-12-02","conditions":"Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma","enrollment":920},{"nctId":"NCT07043400","phase":"PHASE3","title":"A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2025-08-27","conditions":"Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":351},{"nctId":"NCT07469306","phase":"PHASE2","title":"Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2026-08-10","conditions":"Locally Advanced Rectal Cancer","enrollment":130},{"nctId":"NCT06647680","phase":"PHASE2","title":"Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）","status":"RECRUITING","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2025-06-01","conditions":"Rectal Cancer Patients","enrollment":35},{"nctId":"NCT07408609","phase":"PHASE2","title":"Perioperative Chemotherapy With Low-Dose Radiotherapy and Tislelizumab for Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2026-02-26","conditions":"Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":114},{"nctId":"NCT07390383","phase":"PHASE2","title":"A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]","status":"NOT_YET_RECRUITING","sponsor":"Nanjing Leads Biolabs Co.,Ltd","startDate":"2026-03-25","conditions":"Advanced Solid Tumour","enrollment":110},{"nctId":"NCT07385703","phase":"PHASE3","title":"Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.","startDate":"2026-03","conditions":"Adenocarcinoma","enrollment":752},{"nctId":"NCT06206733","phase":"PHASE3","title":"ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AskGene Pharma, Inc.","startDate":"2024-01-25","conditions":"Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma","enrollment":780},{"nctId":"NCT06468280","phase":"PHASE2","title":"Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-11-08","conditions":"Gastric Cancer, GastroEsophageal Cancer","enrollment":84},{"nctId":"NCT07328009","phase":"PHASE2","title":"A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-01-25","conditions":"Hepato Cellular Carcinoma (HCC)","enrollment":350},{"nctId":"NCT07315750","phase":"PHASE3","title":"A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.","status":"RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2026-01-01","conditions":"Gastric Carcinoma","enrollment":555},{"nctId":"NCT06312982","phase":"PHASE2, PHASE3","title":"A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2024-03-16","conditions":"Locally Advanced Rectal Carcinoma","enrollment":375},{"nctId":"NCT07297030","phase":"PHASE2","title":"SIB-RT Combined With CAPOX and PD-1 for High-Risk Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-12-20","conditions":"Rectal Cancer","enrollment":37},{"nctId":"NCT06825494","phase":"PHASE1, PHASE2","title":"Clinical Studies for the Treatment of Advanced Solid Tumors","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-04-08","conditions":"Advanced Solid Tumor","enrollment":194},{"nctId":"NCT05507658","phase":"PHASE2","title":"Tislelizumab Combined With XELOX as Neoadjuvant Therapy for G/GEJ Adenocarcinoma","status":"COMPLETED","sponsor":"Xijing Hospital","startDate":"2022-07-18","conditions":"Locally Advanced Gastric Adenocarcinoma","enrollment":28},{"nctId":"NCT06841679","phase":"PHASE2, PHASE3","title":"Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Beijing Biostar Pharmaceuticals Co., Ltd.","startDate":"2025-08-28","conditions":"Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":778},{"nctId":"NCT07243938","phase":"PHASE2","title":"Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)","status":"NOT_YET_RECRUITING","sponsor":"Tao Zhang","startDate":"2026-01-15","conditions":"Locally Advanced Rectal Cancer (LARC), Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (mCRC)","enrollment":70},{"nctId":"NCT04363801","phase":"PHASE2","title":"A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer","status":"TERMINATED","sponsor":"Leap Therapeutics, Inc.","startDate":"2020-07-29","conditions":"Gastric Cancer, Gastric Adenocarcinoma, GastroEsophageal Cancer","enrollment":247},{"nctId":"NCT07191405","phase":"NA","title":"Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-09-18","conditions":"Immunotherapy, Chemotherapy","enrollment":156},{"nctId":"NCT06124378","phase":"PHASE2","title":"Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2023-11-13","conditions":"Colonic Neoplasms, Neoadjuvant Therapy, Immune Checkpoint Inhibitors","enrollment":60},{"nctId":"NCT05632939","phase":"PHASE1, PHASE2","title":"ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AskGene Pharma, Inc.","startDate":"2023-02-21","conditions":"Gastric Cancer, Gastroesophageal Cancer (GC)","enrollment":62},{"nctId":"NCT06884670","phase":"PHASE2","title":"Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-03-18","conditions":"Rectal Cancer","enrollment":130},{"nctId":"NCT05515796","phase":"PHASE2","title":"Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors","status":"RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2022-09-01","conditions":"Immunotherapy, Gastric Cancer, Rectal Cancer","enrollment":200},{"nctId":"NCT04047862","phase":"PHASE1","title":"Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors","status":"COMPLETED","sponsor":"BeiGene","startDate":"2019-08-15","conditions":"Locally Advanced and Metastatic Solid Tumors","enrollment":446},{"nctId":"NCT07132008","phase":"PHASE3","title":"Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2025-10-01","conditions":"Colonic Neoplasms, Neoadjuvant Therapy, Immune Checkpoint Inhibitors","enrollment":94},{"nctId":"NCT07132463","phase":"PHASE3","title":"Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-08","conditions":"Rectal Cancer","enrollment":154},{"nctId":"NCT06333769","phase":"PHASE2","title":"Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal Cancer","status":"COMPLETED","sponsor":"Fujian Cancer Hospital","startDate":"2024-07-12","conditions":"Mid-low Rectal Cancer","enrollment":38},{"nctId":"NCT07098104","phase":"","title":"A Benefit Population Atlas of nICT Versus nCT for LAGC","status":"COMPLETED","sponsor":"Cheng Chen","startDate":"2019-11-01","conditions":"Gastric Cancer","enrollment":291},{"nctId":"NCT03783442","phase":"PHASE3","title":"A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"BeiGene","startDate":"2018-12-11","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":649},{"nctId":"NCT07070622","phase":"PHASE3","title":"Planed Organ Preservation for Low Rectal Cancer After Neoadjuvant Chemotherapy (OPLAR)","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2024-11-01","conditions":"Rectal Cancer","enrollment":186},{"nctId":"NCT04963088","phase":"PHASE1, PHASE2","title":"Tislelizumab Combined With Anlotinib and Chemotherapy (XELOX) in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (TALENT)","status":"COMPLETED","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2021-03-06","conditions":"Gastric Cancer","enrollment":65},{"nctId":"NCT06507371","phase":"PHASE3","title":"Node-sparing Short-Course Radiation Combined With CAPOX and Tislelizumab for MSS Rectal Cancer","status":"RECRUITING","sponsor":"Sir Run Run Shaw Hospital","startDate":"2024-07-29","conditions":"Rectal Cancer","enrollment":170},{"nctId":"NCT06157996","phase":"PHASE2","title":"Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore","status":"RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2024-06-01","conditions":"Gastric Cancer","enrollment":92},{"nctId":"NCT05941481","phase":"PHASE2","title":"Neoadjuvant Chemo-hypoRT Plus PD-1 Antibody (Tislelizumab) in Resectable LA-G/GEJ","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2023-06-10","conditions":"Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":21},{"nctId":"NCT06818097","phase":"","title":"Efficacy of Target - Immunotherapy and XELOX Chemotherapy for Advanced HCC","status":"COMPLETED","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-10-01","conditions":"Advanced HCC, Systemic Therapy, Chemotherapy","enrollment":68},{"nctId":"NCT06848465","phase":"PHASE1","title":"LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis","status":"RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2025-02-28","conditions":"Colorectal Cancer, Liver Metastasis, LDRT","enrollment":9},{"nctId":"NCT06944496","phase":"PHASE3","title":"A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2025-05-15","conditions":"Gastric Carcinoma","enrollment":616},{"nctId":"NCT06888037","phase":"PHASE2","title":"Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-03-31","conditions":"Gastric Adenocarcinoma, GEJ Adenocarcinoma, First-line Therapy","enrollment":55},{"nctId":"NCT05299476","phase":"PHASE2","title":"CAPOX + Bevacizumab + Tislelizumab Treating PD-L1 CPS < 5 Locally Advanced or Metastatic GEA","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2022-04-25","conditions":"Advanced Gastroesophageal Adenocarcinoma, First-line Therapy, PDL1 CPS < 5","enrollment":32},{"nctId":"NCT06881537","phase":"PHASE2","title":"CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer","status":"RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2024-06-01","conditions":"Locally Recurrent Colorectal Cancer","enrollment":15},{"nctId":"NCT06835179","phase":"PHASE2","title":"SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-02","conditions":"Unresectable Metastatic Colorectal Cancer, Microsatellite Stable (MSS) Colorectal Cancer (CRC), RAS-mutant Colorectal Cancer","enrollment":28},{"nctId":"NCT03777657","phase":"PHASE3","title":"Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma","status":"COMPLETED","sponsor":"BeiGene","startDate":"2018-12-13","conditions":"Gastric, or Gastroesophageal Junction Adenocarcinoma","enrollment":997},{"nctId":"NCT05972655","phase":"PHASE2","title":"Nodes-sparing Short-course Radiation Combined With CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer","status":"RECRUITING","sponsor":"Sir Run Run Shaw Hospital","startDate":"2023-08-02","conditions":"Low Rectal Cancer","enrollment":32},{"nctId":"NCT04276493","phase":"PHASE1, PHASE2","title":"Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab","status":"COMPLETED","sponsor":"BeiGene","startDate":"2020-03-26","conditions":"Breast Cancer, Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":71},{"nctId":"NCT06709885","phase":"PHASE2","title":"HDAC Inhibitor Combination with Chemoimmunotherapy in the Neoadjuvant Treatment of PMMR Locally Advanced Colon Cancer","status":"RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2024-10-15","conditions":"Colon Adenocarcinoma","enrollment":100},{"nctId":"NCT03469557","phase":"PHASE2","title":"BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma","status":"COMPLETED","sponsor":"BeiGene","startDate":"2017-07-18","conditions":"Esophageal Squamous Cell Carcinoma, Gastric Carcinoma, Gastroesophageal Junction Carcinoma","enrollment":30},{"nctId":"NCT05086627","phase":"PHASE2","title":"Short-course Radiotherapy Followed by Tislelizumab + CapeOX in the Treatment for Locally Advanced Rectal Cancer","status":"COMPLETED","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2021-09-01","conditions":"Locally Advanced Rectal Cancer","enrollment":118},{"nctId":"NCT06504875","phase":"","title":"Application of PD-1 Monoclonal Antibody in Combination With IL-2 and CapeOX in Organ Preservation Therapy for Ultra-Low Localized Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-07-10","conditions":"Rectal Cancer","enrollment":23},{"nctId":"NCT06504901","phase":"","title":"Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-07-10","conditions":"Colorectal Cancer","enrollment":30},{"nctId":"NCT06469060","phase":"PHASE2","title":"Neoadjuvant Immunochemotherapy for Adenocarcinoma of the Esophagogastric Junction","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2024-06-19","conditions":"Esophageal Cancer","enrollment":34},{"nctId":"NCT06451211","phase":"PHASE2","title":"Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-05-17","conditions":"Stomach Neoplasms, Gastric Cancer, Linitis Plastica of Stomach","enrollment":53},{"nctId":"NCT06443671","phase":"PHASE2, PHASE3","title":"Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2024-06-01","conditions":"Rectal Cancer","enrollment":132},{"nctId":"NCT06390982","phase":"PHASE2","title":"Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 Study","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-05","conditions":"RECTAL NEOPLASMS, Rectal Cancer","enrollment":46},{"nctId":"NCT06202716","phase":"PHASE2","title":"Cadonilimab Plus CapeOX as First-Line Treatment for Advanced GC/GEJC With High TMEscore","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2024-04","conditions":"Gastric Cancer","enrollment":50},{"nctId":"NCT06254521","phase":"PHASE2","title":"The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer","status":"RECRUITING","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2024-02-22","conditions":"Rectal Cancer, Rectal Cancer Stage II, Rectal Cancer Stage III","enrollment":60},{"nctId":"NCT06238752","phase":"PHASE2","title":"First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GC","status":"COMPLETED","sponsor":"Renmin Hospital of Wuhan University","startDate":"2021-03-01","conditions":"Advanced Gastric Adenocarcinoma","enrollment":33},{"nctId":"NCT06121700","phase":"PHASE2","title":"Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-01-01","conditions":"Adenocarcinoma, Stomach Neoplasm, Gastroesophageal-junction Cancer","enrollment":55},{"nctId":"NCT06017583","phase":"PHASE3","title":"Neoadjuvant Chemotherapy With PD-1 Inhibitors Combined With SIB-IMRT in the Treatment of Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Yong Zhang,MD","startDate":"2023-09-01","conditions":"Rectal Neoplasms","enrollment":48},{"nctId":"NCT05176964","phase":"","title":"Chemotherapy and Tislelizumab With Split-course HFRT for Locally Advanced Rectal Cancer","status":"UNKNOWN","sponsor":"Fujian Medical University Union Hospital","startDate":"2021-12-31","conditions":"Rectal Cancer, Radiation Oncology","enrollment":50},{"nctId":"NCT05970302","phase":"PHASE2","title":"XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-07-07","conditions":"Tislelizumab, Bevacizumab, Oxaliplatin","enrollment":52},{"nctId":"NCT05479240","phase":"PHASE2","title":"Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2023-09-01","conditions":"Immunotherapy","enrollment":94},{"nctId":"NCT05420584","phase":"PHASE2","title":"Neoadjuvant Arterial Embolization Chemotherapy Combined PD-1 Inhibitor for Locally Advanced Rectal Cancer","status":"UNKNOWN","sponsor":"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","startDate":"2022-11-29","conditions":"Rectal Neoplasms","enrollment":83},{"nctId":"NCT05841134","phase":"PHASE2","title":"Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2023-06-01","conditions":"MSI-H Colorectal Cancer, Tislelizumab, Oxaliplatin","enrollment":25},{"nctId":"NCT05536102","phase":"PHASE2","title":"The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2022-09-05","conditions":"Gastric Cancer","enrollment":38},{"nctId":"NCT05359393","phase":"PHASE2","title":"A Combination Therapy Including Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Distal Metastasis","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2022-12-01","conditions":"Advanced Rectal Cancer, Liver Metastasis, Pulmonary Metastasis","enrollment":52},{"nctId":"NCT05291052","phase":"PHASE2","title":"Tisleizumab Combined With Lenvatinib and XELOX Regimen (Oxaliplatin Combined With Capecitabine) in the First-line Treatment of Advanced and Unresectable Biliary Tract Tumors","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-02-14","conditions":"Biliary Tract Tumor","enrollment":20},{"nctId":"NCT04443543","phase":"PHASE2","title":"An Adaptive-design Prospective Cohort Study of Watch and Wait Strategy in Patients With Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2020-06-22","conditions":"Rectal Cancer","enrollment":222}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Tislelizumab+Oxaliplatin+Capecitabine","genericName":"Tislelizumab+Oxaliplatin+Capecitabine","companyName":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","companyId":"chia-tai-tianqing-pharmaceutical-group-nanjing-shunxin-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses a PD-1 inhibitor to enhance immune response against cancer cells while chemotherapy agents directly kill rapidly dividing cells. Used for Gastric or gastroesophageal junction cancer (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}